Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.31 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2889001 | 1.00 | CTSB (0.44) | CTSBPPP3CBCYP3A4ABCC1ABCC2 | |
| SCHEMBL13026234 | 0.95 | CTSB (0.40) | CTSBPPP3CBCYP3A4 | |
| SCHEMBL2894812 | 0.91 | AAK1 (0.34) | CTSBPPP3CBAAK1 | |
| SCHEMBL8221244 | 0.91 | AAK1 (0.34) | CTSBPPP3CBAAK1 | |
| SCHEMBL13026231 | 0.85 | CYP3A4 (0.47) | CYP3A4 | |
| SCHEMBL13026228 | 0.83 | AAK1 (0.35) | CTSBPPP3CBAAK1 | |
| SCHEMBL2894467 | 0.83 | AAK1 (0.35) | CTSBPPP3CBAAK1 | |
| SCHEMBL2897382 | 0.77 | CYP3A4 (0.45) | CTSBPPP3CBCYP3A4 | |
| SCHEMBL375308 | 0.75 | CTSB (0.56) | CTSBPPP3CBCYP3A4ABCC1ABCC2 | |
| SCHEMBL13668840 | 0.75 | CTSB (0.40) | CTSBPPP3CBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2083844-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8377874-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | CTSB 69/4885PPP3CB 250/4885CYP3A4 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.